"TriSalus Life Sciences, Inc. (TLSI) reported a 52% year-over-year revenue increase to $11.2 million in Q2, exceeding revenue estimates, but still posted a loss, raising concerns about profitability. While the company reiterated its 2025 guidance, risks remain due to ongoing challenges in the market, reflected in a moderate sentiment score of 0.36."